Veradermics, Incorporated
MANE
$105.32
-5.31%
Veradermics, Incorporated is a clinical-stage biopharmaceutical company focused on developing therapeutics for prevalent aesthetic and dermatological conditions, operating in a single segment. As a niche player in the dermatology space, it distinguishes itself by targeting pervasive treatment challenges with innovative solutions. The current investor narrative centers on the company's rapid post-IPO momentum, driven by promising pipeline developments and strong analyst enthusiasm, despite its lack of revenue and ongoing losses. The stock has attracted significant attention due to its high growth potential and the recent surge in its market capitalization.…
MANE
Veradermics, Incorporated
$105.32
Investment Opinion: Should I buy MANE Today?
Based on the analysis, MANE is rated a Buy, driven by strong analyst consensus (Strong Buy, mean 1.14) and an average target price of $163.50, implying 45.1% upside. The thesis rests on the company's promising dermatology pipeline, ample cash runway, and the potential for significant revenue growth as it advances toward commercialization.
Sign up to view all
MANE 12-Month Price Forecast
The AI assessment leans bullish, driven by the unanimous analyst support and the company's strong cash position, which mitigates near-term funding risks. However, the lack of revenue and negative equity introduce significant uncertainty, warranting a medium confidence level. The stock's high valuation and dependence on pipeline success mean that any negative news could quickly reverse the bullish outlook. Upgrades would occur if the company announces positive clinical data or secures a major partnership, while downgrades would follow any trial failures or delays.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Veradermics, Incorporated's 12-month outlook, with a consensus price target around $163.50 and implied upside of +55.2% versus the current price.
Average Target
$163.50
0 analysts
Implied Upside
+55.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$135 - $182
Analyst target range
Veradermics is covered by 6 analysts, all with a 'Strong Buy' consensus (mean recommendation of 1.14). The average target price is $163.50, implying a 45.1% upside from the current price of $112.71. The target range spans from $135.00 (low) to $182.00 (high), with the high target suggesting a 61.5% upside, reflecting optimism about pipeline success and market opportunity. The low target still implies a 19.8% upside, indicating that even the most conservative analyst sees value. Recent ratings from Jefferies, Citigroup, and Leerink Partners are all positive (Buy/Outperform), with no downgrades, signaling strong institutional confidence. The relatively narrow spread between low and high targets (34.8% of the average) suggests moderate conviction, though the overall bullish stance is clear.
Bulls vs Bears: MANE Investment Factors
Veradermics presents a classic high-risk, high-reward clinical-stage biotech opportunity. The bull case is anchored by unanimous analyst optimism, a strong cash runway, and impressive post-IPO momentum, while the bear case centers on the absence of revenue, escalating losses, and a valuation that prices in substantial future success. Currently, the bull side has stronger evidence given the strong analyst conviction and ample liquidity, but the most critical tension is whether the pipeline can deliver clinical and regulatory milestones that justify the current market cap of $1.32 billion. Any setback in trials or delays in commercialization could trigger a sharp re-rating, making the stock highly binary.
Bullish
- Strong Buy consensus with 45% upside: All 6 analysts rate MANE a Strong Buy (mean recommendation 1.14), with an average target price of $163.50, implying a 45.1% upside from the current $112.71. Even the lowest target of $135.00 offers a 19.8% gain, reflecting high institutional confidence in the pipeline.
- Robust cash position of $168.4M: At Q1 2026, MANE holds $168.4 million in cash with a current ratio of 16.66, providing ample runway to fund clinical trials and operations. This liquidity reduces near-term dilution risk and supports continued R&D investment.
- Strong price momentum since IPO: The stock has surged 159.34% over the past 6 months, from $47.38 at IPO to $112.71, and trades at 82.5% of its 52-week range. This momentum reflects growing investor enthusiasm for its dermatology pipeline and market opportunity.
- High analyst revenue estimates: Analysts project average revenue of $533.5 million for the next fiscal year, with a high estimate of $1.75 billion, signaling expectations of successful commercialization. This optimism underpins the bullish price targets.
Bearish
- Pre-revenue with widening losses: MANE reported zero revenue in Q1 2026 and a net loss of -$27.23 million, up from -$21.85 million in Q4 2025. R&D expenses rose to $20.93 million, indicating escalating cash burn typical of clinical-stage biotechs.
- Negative equity and high valuation risk: The company has negative equity (PB ratio -10.94) due to accumulated losses, and its forward PE of -41.94 implies the market expects further losses. This makes valuation highly speculative and sensitive to pipeline setbacks.
- High short interest and volatility: With a short ratio of 7.6 and a max drawdown of -21.47%, the stock is prone to sharp corrections. The 1-month price change of -8.88% and relative strength of -11.73% vs. the S&P 500 indicate recent underperformance and potential bearish pressure.
- Dependence on external financing: Operating cash flow was -$21.17 million in Q1 2026, and the company raised $269.1 million from stock issuance, highlighting reliance on capital markets. Future dilution could pressure the stock price if cash runs low.
MANE Technical Analysis
Veradermics has exhibited a robust uptrend since its listing in February 2026, with the stock price surging from an initial close of $47.38 to $112.71 as of August 14, 2026, representing a 1-year price change of 159.34% (6-month change). The current price sits at 82.5% of its 52-week range (between $32.00 low and $131.24 high), indicating strong momentum but also potential overextension. This positioning near the highs suggests bullish sentiment, though investors should be cautious of a possible pullback given the rapid ascent.
Beta
—
—
Max Drawdown
-21.5%
Largest decline past year
52-Week Range
$32-$131
Price range past year
Annual Return
—
Cumulative gain past year
| Period | MANE Return | S&P 500 |
|---|---|---|
| 1m | -3.8% | +1.9% |
| 3m | +3.6% | +2.3% |
| 6m | +136.7% | +10.6% |
| 1y | — | +19.5% |
| ytd | — | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MANE Fundamental Analysis
Veradermics is a pre-revenue clinical-stage biotech, with zero revenue reported in the latest quarter (Q1 2026) and no gross profit. The company's net loss widened to -$27.23 million in Q1 2026 from -$21.85 million in Q4 2025, reflecting increased R&D spending of $20.93 million. The trajectory shows escalating losses as the company advances its pipeline, which is typical for clinical-stage firms but underscores the need for successful development and eventual commercialization. The company's balance sheet shows a strong cash position of $168.4 million at the end of Q1 2026, with a current ratio of 16.66, indicating ample liquidity. However, operating cash flow was -$21.17 million in Q1 2026, and the company relies on external financing, having raised $269.1 million from stock issuance in Q1 2026. The debt-to-equity ratio is near zero, but the negative equity (due to accumulated losses) and negative free cash flow of -$21.17 million highlight the financial risk typical of early-stage biotechs.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MANE Overvalued?
Given the negative net income, the price-to-sales ratio is not meaningful (PS = 0), so we rely on the price-to-earnings ratio, which is -15.86 trailing and -41.94 forward. The negative PE reflects current losses, but the forward PE being more negative suggests the market expects further losses, indicating high growth expectations. The company's EV/EBITDA is -18.61, also negative, consistent with its unprofitable status. Peer comparison is challenging due to lack of industry averages, but the negative multiples are typical for clinical-stage biotechs with no revenue. Historically, the PE ratio has been negative since inception, and the current valuation is not directly comparable to historical ranges due to the company's early stage. The market is pricing in significant future potential, as evidenced by the high price-to-book ratio of -10.94 (negative due to negative equity) and the analyst consensus target price implying substantial upside.
PE
-15.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-18.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant for Veradermics. The company is pre-revenue, with zero sales and a net loss of -$27.23 million in Q1 2026, up from -$21.85 million in Q4 2025. R&D expenses of $20.93 million are driving cash burn, and operating cash flow was -$21.17 million. While the $168.4 million cash position provides a cushion, the negative equity (PB -10.94) and reliance on external financing (raised $269.1 million in Q1) expose the company to dilution risk if capital markets tighten. The forward PE of -41.94 indicates the market expects continued losses, and any delay in reaching profitability could strain the balance sheet.
FAQ
The key risks are: (1) Clinical trial failures, which could cause the stock to plummet to the 52-week low of $32.00. (2) Financial risk from negative equity and reliance on external financing, with a cash burn of -$21.17 million per quarter. (3) Market risk from high short interest (7.6) and volatility, with a max drawdown of -21.47%. (4) Competitive risk from larger dermatology companies. The most severe risk is a pipeline setback, which would likely lead to significant dilution and a sharp decline in share price.
The 12-month forecast is bullish, with a base case target of $163.50 (45.1% upside) and a bull case target of $182.00 (61.5% upside). The bear case could see the stock fall to $32.00 (-71.6%) if clinical trials fail. The most likely scenario is the base case, with a 45% probability, assuming steady pipeline progress. The stock's future hinges on successful development and commercialization of its dermatology pipeline.
MANE is overvalued based on traditional metrics, with a negative PE of -15.86 and no revenue, making the PS ratio meaningless. The market is pricing in significant future potential, as evidenced by the high price-to-book ratio of -10.94 (negative equity). However, the analyst target price of $163.50 suggests the stock is undervalued relative to expected pipeline success. The valuation implies the market expects the company to successfully commercialize its dermatology products and generate substantial revenue, which is a high bar.
MANE is a high-risk, high-reward opportunity. With a Strong Buy consensus and an average target price of $163.50, implying 45.1% upside, the stock has significant potential. However, it is pre-revenue with widening losses, and the valuation is speculative. A good buy for investors who can tolerate high volatility and have a long-term horizon, but not suitable for conservative investors. The biggest downside risk is a clinical failure, which could lead to a -71.6% drop to the 52-week low of $32.00.
MANE is more suitable for long-term investment, given its clinical-stage nature and the time required for pipeline development and commercialization. The stock is highly volatile, with a beta-like sensitivity to market swings, making it risky for short-term trading. A minimum holding period of 3-5 years is recommended to allow for clinical milestones and potential revenue generation. Short-term traders may find opportunities in the volatility, but the risk is elevated.